Trial Profile
A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 11 Mar 2019 Results assessing pharmacokinetic (PK) data from nine clinical trials (NCT00512486, NCT00659659, NCT00768079, NCT00783289, NCT01238861, NCT01928771, NCT01914757, NCT02322775, NCT02075255) for patients with asthma, published in the Clinical Pharmacokinetics.
- 08 Jan 2016 Pooled analysis of 2 trials including 14 patients from this study and other study (see CTP700038860) were published in the Respiratory Medicine.
- 31 Jul 2012 Actual initiation date changed from May 2008 to Jan 2008, and additional lead investigator (Gossage D) added as reported by ClinicalTrials.gov.